BioSpace News Archive

As part of Sickle Cell Disease Awareness Month in September, The National Marrow Donor Program® /Be The Match® is sharing the Sickle Cell Warrior Program, an initiative designed to eliminate barriers to equitable care, facilitate early referral and typing, and provide resources to empower warriors and caregivers.

AGAE Technologies, LLC, an Oregon-based leading specialty green chemical and biotech company, has discovered how to use selected strains and media under optimized fermentation conditions to achieve record-high yields of rhamnolipids at its lowest production cost.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen,

Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, provides an update on it AcuVid™ COVID-19 Rapid Antigen Saliva Test’s Emergency Use Authorization application with the U.S. Food and Drug Administration.

The induced pluripotent stem cells production market has been estimated to reach a CAGR of 8.0% in the foreseeable years from 2021 to 2031.

The recent research studies predict that the global pharmacovigilance market will record a stellar compound annual growth rate of 10.5 % over the forecast period of 2022 to 2030.

The global RNAi Technology Market is on a trajectory that will take the market worth up to an impressive figure by the end of the forecast period of 2021 to 2031, thanks to a steady growth rate, compounded annually, accelerating the growth momentum.

Increasing cancer cases and the rising use of doxorubicin for cancer treatment are the two prime factors that drive doxorubicin market potential in the region of North America.

The demand within the global acute lymphoblastic leukaemia market is poised to rise in the years to come by.

The global combination antibody therapy market has undergone revolutionary progress in the past few years owing to continued focus on development of targeted cancer therapies that lead to fewer side effects.